Karo and Alkem collaborate to develop Eprotirome. Karo bio has granted license to Alkem to commercialize in India and certail countires. Alkem will participate in Karo Bio’s phase III programme for eprotirome by conducting a pivotal clinical study on eprotirome in India.
Eprotirome seems to be protected by 206517 (IN/PCT/2002/00888/MUM) and its pending divisional (139/MUMNP/2007) protects combination with other drugs. This patent is assigned to BMS. Karo Bio has another new drug research collaboration with Zydus too.